Introduction. Gliptins (DPP-4 inhibitors) entered Russian medical practice in 2011 and were included in the first line of glucose-lowering therapy [1], Today, DPP-4 inhibitor drugs are widely used in real clinical practice [2]. The emergence of new pharmaceutical substances, the development by domestic pharmaceutical enterprises of drugs with gliptins, which are in demand in healthcare, with the already existing wide range of drugs in this group, necessitate the systematization of available data on the range and main pharmacological properties of DPP-4 i.d. Target. To study the current state of the market for drugs for the treatment of type 2 diabetes, the group of dipeptylpetidase-4 inhibitors and substances for their production in the Russian Federation, systematize data on the mechanism of their action, pharmacological effects and drug interactions, and determine trends in the further development of the DPP-4 market. Materials and methods. The material for the study was the State Register of Medicines, scientific publications and Internet resources. To obtain the results, the following methods were used: content analysis, information-analytical review of data, situational-logical and statistical analysis. Results and discussion. DPP-4 inhibitors are widely used in the treatment of type 2 diabetes mellitus, which is confirmed by their leading role in prescription and use among all modern classes of glucose-lowering drugs according to the Federal Register of Diabetes Mellitus. According to experts, the real possibilities for the effective use of gliptins are much wider. Drugs in this group have a high safety profile, are convenient for use and storage, since they are mainly presented in the form of tablets and film-coated tablets. The pharmaceutical market of DPP-4 inhibitors in the Russian Federation is quite diverse, and is mainly represented by domestically produced generic drugs. However, gliptins also have disadvantages, such as the need for caution if there is a history of pancreatitis and high price. Conclusion. The increasing need for DPP-4 drugs, coupled with the prospects for expanding clinical use, as well as the high price, make this group of drugs relevant for further study, as well as for the development of drugs with gliptins in the Russian Federation.